137 related articles for article (PubMed ID: 25663537)
1. A unique description of stage IV extranodal marginal zone lymphoma (EMZL) in an adolescent associated with gamma heavy chain disease.
Mittal N; Zhu B; Gaitonde S; Lu Y; Schmidt ML
Pediatr Blood Cancer; 2015 May; 62(5):905-8. PubMed ID: 25663537
[TBL] [Abstract][Full Text] [Related]
2. Nodal marginal-zone lymphoma associated with monoclonal light-chain and heavy-chain deposition disease.
Went P; Ascani S; Strøm E; Brorson SH; Musso M; Zinzani PL; Falini B; Dirnhofer S; Pileri S
Lancet Oncol; 2004 Jun; 5(6):381-3. PubMed ID: 15172359
[No Abstract] [Full Text] [Related]
3. Pneumocystis jirovecii pneumonia as a complication of bendamustine in a patient receiving bendamustine plus rituximab for marginal zone lymphoma.
Carter SJ; Bernstein SH; Friedberg JW; Barr PM
Leuk Res; 2011 Nov; 35(11):e223-4. PubMed ID: 21824654
[No Abstract] [Full Text] [Related]
4. Rare presentation of secondary cutaneous involvement by splenic marginal zone lymphoma: report of a case and review of the literature.
Cohen JM; Nazarian RM; Ferry JA; Takvorian RW; Carter JB
Am J Dermatopathol; 2015 Jan; 37(1):e1-4. PubMed ID: 25238446
[TBL] [Abstract][Full Text] [Related]
5. Bendamustine and rituximab as frontline therapy in extranodal marginal zone lymphoma: a single-institution experience.
Logothetis CN; Horvat NP; Kurian T; Bello C; Chavez J; Isenalumhe L; Shah B; Sokol L; Saeed H; Pinilla J; Gaballa S
Oncol Res; 2024; 32(6):1031-1036. PubMed ID: 38827319
[TBL] [Abstract][Full Text] [Related]
6. Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma).
Kiesewetter B; Mayerhoefer ME; Lukas J; Zielinski CC; Müllauer L; Raderer M
Ann Hematol; 2014 Feb; 93(2):249-53. PubMed ID: 23925930
[TBL] [Abstract][Full Text] [Related]
7. Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients.
Morigi A; Argnani L; Lolli G; Broccoli A; Pellegrini C; Nanni L; Stefoni V; Coppola PE; Carella M; Casadei B; Sabattini E; Cavo M; Zinzani PL
Hematol Oncol; 2020 Oct; 38(4):487-492. PubMed ID: 32594531
[TBL] [Abstract][Full Text] [Related]
8. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
Rummel MJ; Niederle N; Maschmeyer G; Banat GA; von Grünhagen U; Losem C; Kofahl-Krause D; Heil G; Welslau M; Balser C; Kaiser U; Weidmann E; Dürk H; Ballo H; Stauch M; Roller F; Barth J; Hoelzer D; Hinke A; Brugger W;
Lancet; 2013 Apr; 381(9873):1203-10. PubMed ID: 23433739
[TBL] [Abstract][Full Text] [Related]
9. State-of-the-art therapeutics: marginal-zone lymphoma.
Bertoni F; Zucca E
J Clin Oncol; 2005 Sep; 23(26):6415-20. PubMed ID: 16155028
[TBL] [Abstract][Full Text] [Related]
10. Outcome and prognostic factors in ocular adnexal lymphoma.
Nola M; Lukenda A; Bollmann M; Kalauz M; Petrovecki M; Bollmann R
Croat Med J; 2004 Jun; 45(3):328-32. PubMed ID: 15185428
[TBL] [Abstract][Full Text] [Related]
11. Treatment of gastric marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue with rituximab, cyclophosphamide, vincristine and prednisone.
Aguiar-Bujanda D; Llorca-Mártinez I; Rivero-Vera JC; Blanco-Sánchez MJ; Jiménez-Gallego P; Mori-De Santiago M; Limeres-Gonzalez MA; Cabrera-Marrero JC; Hernández-Sosa M; Galván-Ruíz S; Hernández-Sarmiento S; Saura Grau S; Bohn-Sarmiento U
Hematol Oncol; 2014 Sep; 32(3):139-44. PubMed ID: 24123108
[TBL] [Abstract][Full Text] [Related]
12. Primary extranodal marginal zone lymphoma involving the skull.
Rasouli J; Patel SA; Skovrlj B; Gologorsky Y; Mascitelli J; Petersen B; Caridi J
J Clin Neurosci; 2014 Feb; 21(2):351-3. PubMed ID: 24094361
[TBL] [Abstract][Full Text] [Related]
13. Bilateral conjunctival extranodal marginal zone B-cell lymphoma.
Kram DE; Brathwaite CD; Khatib ZA
Pediatr Blood Cancer; 2010 Dec; 55(7):1414-6. PubMed ID: 20981695
[TBL] [Abstract][Full Text] [Related]
14. Stage IV marginal zone B-cell lymphoma--prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) study.
Oh SY; Kim WS; Kim JS; Kim SJ; Lee S; Lee DH; Won JH; Hwang IG; Kim MK; Lee SI; Chae YS; Yang DH; Kang HJ; Choi CW; Park J; Kim HJ; Kwon JH; Lee HS; Lee GW; Eom HS; Kwak JY; Suh C; Kim HJ
Cancer Sci; 2010 Nov; 101(11):2443-7. PubMed ID: 20831770
[TBL] [Abstract][Full Text] [Related]
15. Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.
Ogura M; Ando K; Taniwaki M; Watanabe T; Uchida T; Ohmachi K; Matsumoto Y; Tobinai K;
Cancer Sci; 2011 Sep; 102(9):1687-92. PubMed ID: 21624007
[TBL] [Abstract][Full Text] [Related]
16. Primary extranodal marginal zone B-cell lymphoma of the female genital tract: a case report and literature review.
Heeren JH; Croonen AM; Pijnenborg JM
Int J Gynecol Pathol; 2008 Apr; 27(2):243-6. PubMed ID: 18317217
[TBL] [Abstract][Full Text] [Related]
17. Extranodal marginal zone lymphoma in the ocular region: clinical, immunophenotypical, and cytogenetical characteristics.
Sjö LD; Heegaard S; Prause JU; Petersen BL; Pedersen S; Ralfkiaer E
Invest Ophthalmol Vis Sci; 2009 Feb; 50(2):516-22. PubMed ID: 18775860
[TBL] [Abstract][Full Text] [Related]
18. Rare Orbital Involvement Originating from Extranodal Marginal Zone Lymphoma.
Wen YC; Huang TC; Tsai WC; Lai SW
Medicina (Kaunas); 2024 Apr; 60(5):. PubMed ID: 38792889
[TBL] [Abstract][Full Text] [Related]
19. An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma.
Alderuccio JP; Arcaini L; Watkins MP; Beaven AW; Shouse G; Epperla N; Spina M; Stefanovic A; Sandoval-Sus J; Torka P; Alpert AB; Olszewski AJ; Kim SH; Hess B; Gaballa S; Ayyappan S; Castillo JJ; Argnani L; Voorhees TJ; Saba R; Chowdhury SM; Vargas F; Reis IM; Kwon D; Alexander JS; Zhao W; Edwards D; Martin P; Cencini E; Kamdar M; Link BK; Logothetis CN; Herrera AF; Friedberg JW; Kahl BS; Luminari S; Zinzani PL; Lossos IS
Blood Adv; 2022 Apr; 6(7):2035-2044. PubMed ID: 35196377
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type.
Salar A; Domingo-Domenech E; Estany C; Canales MA; Gallardo F; Servitje O; Fraile G; Montalbán C
Cancer; 2009 Nov; 115(22):5210-7. PubMed ID: 19672998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
